Antiretroviral therapy in developing countries: pharmacologic considerations

被引:0
|
作者
Lamorde, Mohammed [1 ,2 ]
Byakika-Kibwika, Pauline [1 ,2 ,4 ]
Merry, Concepta [1 ,2 ,3 ]
机构
[1] Makerere Univ, Infect Dis Inst, Fac Med, Kampala, Uganda
[2] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland
[3] Acad Alliance AIDS Care & Prevent Africa, Arlington, VA USA
[4] Makerere Univ, Dept Med, Kampala, Uganda
关键词
anti-HIV agents; developing countries; drug interactions; pharmacokinetics; toxicity;
D O I
10.1097/COH.0b013e3282f7cd7f
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review This article reviews recent studies in the field of clinical pharmacology of antiretroviral drugs and highlights the relevance of the findings to clinical practice in developing countries. Recent findings Differences in antiretroviral pharmacokinetics are associated with polymorphisms of genes encoding drug metabolizing enzymes. Inadequate concentrations of antiretrovirals in children are common. A study in African children found subtherapeutic concentrations in 40% of patients receiving efavirenz at recommended doses. Summary Recent findings on the pharmacokinetics of antiretroviral agents relevant to clinical practice in developing countries are reviewed. Widespread poverty impacts negatively on HIV/AIDS treatment and prevention efforts. Improved access to treatment, social and economic support and pharmacology research in target populations are needed.
引用
收藏
页码:252 / 257
页数:6
相关论文
共 50 条